National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedWurcel AG, Guardado R, Grussing ED
Racial differences in testing for infectious diseases: an analysis of jail intake data.
This analysis examines HIV and hepatitis C virus (HCV) testing in Middlesex House of Corrections (MHOC) in Massachusetts. Only 38% of incarcerated individuals who requested testing received it. Black non-Hispanic and Hispanic individuals were more likely to request and complete testing compared to white individuals. These disparities may reflect broader issues of access to care. The study highlights the need for improved testing completion rates and interdisciplinary collaboration in jails.
AHRQ-funded; HS026008.
Citation: Wurcel AG, Guardado R, Grussing ED .
Racial differences in testing for infectious diseases: an analysis of jail intake data.
PLoS One 2023 Dec 20; 18(12):e0288254. doi: 10.1371/journal.pone.0288254.
Keywords: Hepatitis, Human Immunodeficiency Virus (HIV), Racial and Ethnic Minorities, Vulnerable Populations
Wurcel AG, Reyes J, Zubiago J
"I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
Despite national guidelines promoting hepatitis C virus (HCV) testing in prisons, there is substantial heterogeneity on the implementation of HCV testing in jails. IN this study, the investigators sought to better understand barriers and opportunities for HCV testing by interviewing a broad group of stakeholders involved in HCV testing and treatment policies and procedures in Massachusetts jails.
AHRQ-funded; HS026008.
Citation: Wurcel AG, Reyes J, Zubiago J .
"I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
PLoS One 2021 May 26;16(5):e0250901. doi: 10.1371/journal.pone.0250901..
Keywords: Hepatitis, Vulnerable Populations, Screening, Prevention, Public Health, Social Stigma
Beckman AL, Bilinski A, Boyko R
New hepatitis C drugs are very costly and unavailable to many state prisoners.
This study found that in the forty-one states whose departments of corrections reported data, 106,266 inmates (10 percent of their prisoners) were known to have hepatitis C on or about January 1, 2015. Only 949 of those inmates were being treated. Prices for a twelve-week course of direct-acting antivirals such as sofosbuvir and the combination drug ledipasvir/sofosbuvir varied widely as of September 30, 2015 ($43,418-$84,000 and $44,421-$94,500, respectively).
AHRQ-funded; HS000055.
Citation: Beckman AL, Bilinski A, Boyko R .
New hepatitis C drugs are very costly and unavailable to many state prisoners.
Health Aff 2016 Oct;35(10):1893-901. doi: 10.1377/hlthaff.2016.0296.
.
.
Keywords: Access to Care, Healthcare Costs, Hepatitis, Medication, Vulnerable Populations